Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (now GSK plc) covers the month of May 2022, specifically dated May 16, 2022. The primary purpose of this report is to confirm the official change of the registrant's name from GlaxoSmithKline plc to GSK plc, a decision previously announced on April 27, 2022, alongside first-quarter 2022 results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely as a corporate governance notice regarding the name change and does not contain financial statements or performance data.
Material Changes
- Corporate Name: The company's legal name has officially changed from GlaxoSmithKline plc to GSK plc.
- Shareholder Impact: Shareholdings remain unaffected by the name change.
- Documentation: Existing share certificates remain valid; no new certificates will be issued.
- Identifiers: ISINs, SEDOLs, CUSIPs, ticker symbols, and the Legal Entity Identifier (LEI) remain unchanged.
Guidance, Outlook, and Risks
The filing does not provide guidance, outlook, management commentary on financial performance, risks, contingencies, or unusual items. The only forward-looking statement indicates that the London Stock Exchange and the New York Stock Exchange will reflect the name change in due course.
Key Facts for Investor Verification
- Confirm the ticker symbol and trading name updates on relevant exchanges (LSE and NYSE) to reflect "GSK plc".
- Verify that existing share certificates and account holdings remain valid without action required from shareholders.
- Ensure the Legal Entity Identifier (5493000HZTVUYLO1D793) is correctly associated with the new name in internal systems.